Communiqués Imugene Limited

Actions

IMU

AU000000IMU9

Recherche biotechnologique et médicale

Marché Fermé - Australian S.E. 08:10:15 28/08/2026			Varia. 5j.	Varia. 1 janv.
0,0700 ^AUD	-1,41%		-14,63%	-80,82%

28/08	Imugene Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI
01/07	Imugene : un nouveau patient du groupe BTKi atteint une réponse complète dans l'étude de phase 1b sur l'Azer-Cel, l'action bondit de 26 %	MT

Communiqués

01/12	Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva(R) Combination in Solid Tumours	AQ
04/09/24	Imugene Limited - Investor webinar, Azer-cel trial update	AQ
03/09/24	Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)	AQ
16/04/24	Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million	AQ
15/04/24	Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort	AQ
15/04/24	Imugene opens enrolment for Bile Tract Cancer expansion study	AQ
09/04/24	Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024	AQ
11/03/24	Imugene progresses onCARlytics solid tumour trial to combination arm	AQ
11/03/24	Phase 1 onCARlytics solid tumour trial advances to combination arm treatment	AQ
22/02/24	Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts	AQ
15/02/24	Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial	AQ
23/01/24	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs	AQ
19/01/24	Imugene Limited - VAXINIA MAST oncolytic virus Phase 1 trial doses first patients in higher dose cohorts	AQ
06/12/23	Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial	AQ
28/11/23	Imugene thrilled as VAXINIA granted FDA Fast Track designation	AQ
13/11/23	Imugene says Azer-cel could be best-in-class Allogeneic CAR T	AQ
06/11/23	Imugene sees positive early signals in Phase 1 VAXINIA study	AQ
26/10/23	Imugene thrilled as first patient dosed in Phase 1 OASIS trial	AQ
11/09/23	Imugene welcomes positive FDA feedback on new manufacturing process for azer-cel	AQ
04/09/23	Imugene talks VAXINIA MAST trial and corporate ambition	AQ
01/06/23	Imugene doses first patient in PD1-Vaxx combination trial	AQ
19/05/23	Imugene secures IND approval for first-in-class onCARlytics trial	AQ
05/04/23	Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial	AQ
03/03/23	Imugene thrilled as first patients dosed in VAXINIA MAST combination study	AQ
23/01/23	Imugene off to strong start to 2023 with JP Morgan Healthcare Conference	AQ